PT  - JOURNAL ARTICLE
AU  - Hanady Hegazy
AU  - Neamat Hegazy
AU  - Maher Soliman
AU  - Amr Elsaid
TI  - 363 Study of neoadjuvant chemotherapy with a carboplatin and taxol followed by chemoradiation versus chemoradiation for locally advanced cervical cancer
AID  - 10.1136/ijgc-2020-ESGO.30
DP  - 2020 Dec 01
TA  - International Journal of Gynecologic Cancer
PG  - A14--A15
VI  - 30
IP  - Suppl 4
4099  - http://ijgc.bmj.com/content/30/Suppl_4/A14.2.short
4100  - http://ijgc.bmj.com/content/30/Suppl_4/A14.2.full
SO  - Int J Gynecol Cancer2020 Dec 01; 30
AB  - Introduction/Background The incidence of locally advanced cancer cervix (LACC) in developing countries is still high due to the absence of regular screening programs and vaccination. Besides, the survival in LACC patients remains low. So we conducted this study to evaluate the use of neoadjuvant chemotherapy (NAC) induction before the definitive concomitant chemoradiation (CCR) for downstaging of the tumor.Methodology A 68 patients with LACC (International Federation of Gynecology and Obstetrics FIGO stage IB2 to IVA) randomly assigned to group A (received three cycles of NAC with Carboplatin AUC5 + Taxol 175 mg/m2 followed by the standard CCR with weekly Cisplatin plus 3D conformal pelvic radiotherapy followed by brachytherapy (BT)) and group B ( received the standard CCR and BT). The primary end point: the assessment of response rate and local control. The secondary end points: assessment of the 2 years overall survival (OS) and progression free survival (PFS).Results The median age was 54 years old and a range of 44 years old with a performance status (0, 1). The majority of patients had squamous cell carcinoma (88.24% group A vs. 94.12% group B) and most of the patients were FIGO stage IIIC, IVA and IIB (41.18%, 32.35% and 20.59% in group A vs. 32.35%, 17.65% and 17.65% in group B respectively). CT abdomen and pelvis done at time of diagnosis showed pathological enlarged lymph nodes in 64.71% and 58.82% of patients in group A and B respectively. After NAC, 97.06% of the patients achieved partial response with a reduction of tumor volume by 76.07% and only 2.94% had stable disease. Higher partial response in groups A (55.88% in group A vs. 32.35% in group B, p value 0.151) and higher overall response rate (ORR) in group A (79.41% vs.70.59%) while local control was higher in group B (91.18% vs. 97.06%, p value 0.614). The 2 years PFS was 91% in group A and 97.1% in group B and OS of 100% as all the patients remain alive till the end of the 2 years follow up.Conclusion The addition of NAC to the standard CCR achieved a higher partial response rate and ORR with a reasonable local control of the disease. This can facilitate the CCR plane and subsequently the brachytherapy planning parameters in locally advanced cases with no inferiority of the PFS and OS compared to the standard.Disclosures The authors of this abstract do not have any research support and no conflict of interest.